ELISA Kit for Fetal Hemoglobin (HBF) Homo sapiens (Human) Competition ELISA

hemoglobin F; Foetal Haemoglobin

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Fetal Hemoglobin (HBF) Packages (Simulation)
  • ELISA Kit for Fetal Hemoglobin (HBF) Packages (Simulation)
  • ELISA Kit for Fetal Hemoglobin (HBF) Results demonstration
  • CEA996Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Fetal Hemoglobin (HBF) and the recovery rates were calculated by comparing the measured value to the expected amount of Fetal Hemoglobin (HBF) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-101 96
EDTA plasma(n=5) 80-89 86

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fetal Hemoglobin (HBF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fetal Hemoglobin (HBF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fetal Hemoglobin (HBF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 98-105% 80-94% 87-95%
EDTA plasma(n=5) 84-99% 84-95% 90-104% 81-89%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

ELISA Kit for Fetal Hemoglobin (HBF)

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Fetal Hemoglobin (HBF) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Fetal Hemoglobin (HBF) and unlabeled Fetal Hemoglobin (HBF) (Standards or samples) with the pre-coated antibody specific to Fetal Hemoglobin (HBF). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Fetal Hemoglobin (HBF) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Fetal Hemoglobin (HBF) in the sample.

Citations

  • Elevated levels of protein AMBP in cerebrospinal fluid of women with preeclampsia compared to normotensive pregnant women.pubmed:27615121
  • A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell diseasePubmed: 31147439

Recommend products